研究园简易版
·
经典书籍
·
期刊文章
·
有原文
·
完整版(可多选筛选、搜索)
·
首页
搜索
2018 年 · Clinical Trials(临床试验)
107 篇,新的在前。点标题看作者和摘要。
回到 2018 年
Initial severity‐dependent longitudinal model with application to a randomized controlled trial of women with depression
· SiM · 2018-12-26 · 在第 1 页
Sample size re‐estimation for clinical trials with longitudinal negative binomial counts including time trends
· SiM · 2018-12-21 · 在第 1 页
Bayesian model of disease progression in GNE myopathy
· SiM · 2018-12-03 · 在第 2 页
Nonparametric covariate-adjusted response-adaptive design based on a functional urn model
· AoS · 2018-12-02 · 在第 2 页
Debiasing the lasso: Optimal sample size for Gaussian designs
· AoS · 2018-12-01 · 在第 3 页
Machine learning methods for leveraging baseline covariate information to improve the efficiency of clinical trials
· SiM · 2018-11-25 · 在第 3 页
On the efficiency of adaptive sample size design
· SiM · 2018-11-18 · 在第 4 页
ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage
· SiM · 2018-11-12 · 在第 4 页
Statistical modeling and prediction of clinical trial recruitment
· SiM · 2018-11-08 · 在第 4 页
Admissible multiarm stepped‐wedge cluster randomized trial designs
· SiM · 2018-11-06 · 在第 4 页
Sample size estimation for case‐crossover studies
· SiM · 2018-11-05 · 在第 5 页
Multivariate semi-continuous proportionally constrained two-part fixed effects models and applications
· SMMR · 2018-10-31 · 在第 5 页
A proof-of-concept-to-confirmatory multiple adaptation design in the development of an anti-viral treatment
· SMMR · 2018-10-30 · 在第 5 页
Assessing the influence of treatment nonadherence on noninferiority trials using the tipping point approach
· SiM · 2018-10-28 · 在第 5 页
A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III
· Biometrics · 2018-10-26 · 在第 5 页
Modified power prior with multiple historical trials for binary endpoints
· SiM · 2018-10-25 · 在第 5 页
A Bayesian design for phase I cancer therapeutic vaccine trials
· SiM · 2018-10-25 · 在第 5 页
Minimum sample size for developing a multivariable prediction model: PART II ‐ binary and time‐to‐event outcomes
· SiM · 2018-10-24 · 在第 5 页
Minimum sample size for developing a multivariable prediction model: Part I – Continuous outcomes
· SiM · 2018-10-22 · 在第 6 页
Power and sample size requirements for GEE analyses of cluster randomized crossover trials
· SiM · 2018-10-08 · 在第 6 页
Optimal sample size planning for the Wilcoxon‐Mann‐Whitney test
· SiM · 2018-10-08 · 在第 6 页
Adaptive non-inferiority margins under observable non-constancy
· SMMR · 2018-10-08 · 在第 7 页
Assessment of effect size and power for survival analysis through a binary surrogate endpoint in clinical trials
· SiM · 2018-09-27 · 在第 8 页
Optimal designs for testing hypothesis in multiarm clinical trials
· SMMR · 2018-09-20 · 在第 8 页
A Bayesian adaptive phase II clinical trial design accounting for spatial variation
· SMMR · 2018-09-19 · 在第 8 页
Improving the efficiency of individually randomized clinical trials by staggering the introduction of the intervention
· SiM · 2018-09-17 · 在第 8 页
Auxiliary variable–enriched biomarker‐stratified design
· SiM · 2018-09-16 · 在第 8 页
Theory of general balance applied to step wedge designs
· SiM · 2018-09-12 · 在第 9 页
Relative efficiency of unequal cluster sizes in stepped wedge and other trial designs under longitudinal or cross‐sectional sampling
· SiM · 2018-09-12 · 在第 9 页
Interim monitoring using the adaptively weighted log‐rank test in clinical trials for survival outcomes
· SiM · 2018-09-12 · 在第 9 页
Power and Sample Size for Dose-Finding Studies with Survival Endpoints Under Model Uncertainty
· Biometrics · 2018-09-11 · 在第 9 页
Adaptive enrichment designs for confirmatory trials
· SiM · 2018-09-11 · 在第 9 页
Half blind superiority tests for clinical trials of anti‐infective drugs
· SiM · 2018-09-10 · 在第 9 页
Designing cancer immunotherapy trials with random treatment time‐lag effect
· SiM · 2018-09-10 · 在第 9 页
An alternative method to analyse the biomarker‐strategy design
· SiM · 2018-09-09 · 在第 9 页
Inference for the treatment effect in multiple-period cluster randomised trials when random effect correlation structure is misspecified
· SMMR · 2018-09-07 · 在第 9 页
Use of a random effects meta‐analysis in the design and analysis of a new clinical trial
· SiM · 2018-09-06 · 在第 9 页
Underestimation of treatment effects in sequentially monitored clinical trials that did not stop early for benefit
· SMMR · 2018-08-22 · 在第 10 页
Efficiency and robustness of causal effect estimators when noncompliance is measured with error
· SiM · 2018-08-14 · 在第 10 页
Reliably picking the best endpoint
· SiM · 2018-08-08 · 在第 11 页
Design and estimation in clinical trials with subpopulation selection
· SiM · 2018-08-07 · 在第 11 页
Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS)
· SiM · 2018-08-06 · 在第 11 页
Information Content of Cluster–Period Cells in Stepped Wedge Trials
· Biometrics · 2018-07-27 · 在第 12 页
Randomization: The forgotten component of the randomized clinical trial
· SiM · 2018-07-25 · 在第 12 页
A practical Bayesian adaptive design incorporating data from historical controls
· SiM · 2018-07-22 · 在第 13 页
Quantifying and presenting overall evidence in network meta‐analysis
· SiM · 2018-07-18 · 在第 13 页
A Bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs)
· SiM · 2018-07-16 · 在第 13 页
A Useful Design Utilizing the Information Fraction in a Group Sequential Clinical Trial With Censored Survival Data
· Biometrics · 2018-07-13 · 在第 13 页
Optimal unidirectional switch designs
· SiM · 2018-07-12 · 在第 13 页
A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect
· Biometrics · 2018-07-10 · 在第 14 页
Bayesian basket trial design with exchangeability monitoring
· SiM · 2018-07-08 · 在第 14 页
Sample size for binary logistic prediction models: Beyond events per variable criteria
· SMMR · 2018-07-03 · 在第 14 页
A Bayesian Phase I/II Trial Design for Immunotherapy
· JASA · 2018-06-28 · 在第 15 页
Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup
· SiM · 2018-06-26 · 在第 15 页
Bayesian design of a survival trial with a cured fraction using historical data
· SiM · 2018-06-25 · 在第 15 页
Dynamic development paths for expanding a proof‐of‐concept study to explore dose range
· SiM · 2018-06-21 · 在第 16 页
Statistical analysis of Goal Attainment Scaling endpoints in randomised trials
· SMMR · 2018-06-19 · 在第 16 页
Sample Size Determination for GEE Analyses of Stepped Wedge Cluster Randomized Trials
· Biometrics · 2018-06-19 · 在第 16 页
Interval and point estimation in adaptive Phase II trials with binary endpoint
· SMMR · 2018-06-19 · 在第 16 页
Hazard ratio estimation and inference in clinical trials with many tied event times
· SiM · 2018-06-13 · 在第 16 页
Bayesian selective response‐adaptive design using the historical control
· SiM · 2018-06-13 · 在第 16 页
Group sequential designs with robust semiparametric recurrent event models
· SMMR · 2018-06-11 · 在第 17 页
Sample size calculation for studies with grouped survival data
· SiM · 2018-06-10 · 在第 17 页
Efficient design of cluster randomized trials with treatment‐dependent costs and treatment‐dependent unknown variances
· SiM · 2018-06-10 · 在第 17 页
A noniterative sample size procedure for tests based on t distributions
· SiM · 2018-06-06 · 在第 18 页
Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure
· SMMR · 2018-06-05 · 在第 18 页
Quantitative Evaluation of the Trade-Off of Strengthened Instruments and Sample Size in Observational Studies
· JASA · 2018-06-05 · 在第 18 页
Bayesian Optimal Interval Design with Multiple Toxicity Constraints
· Biometrics · 2018-06-05 · 在第 18 页
A comparative study of restricted randomization procedures for multiarm trials with equal or unequal treatment allocation ratios
· SiM · 2018-06-04 · 在第 18 页
Point estimation following two‐stage adaptive threshold enrichment clinical trials
· SiM · 2018-05-31 · 在第 19 页
On the propensity score weighting analysis with survival outcome: Estimands, estimation, and inference
· SiM · 2018-05-31 · 在第 19 页
Extensions to the two‐stage randomized trial design for testing treatment, self‐selection, and treatment preference effects to binary outcomes
· SiM · 2018-05-31 · 在第 19 页
Bayesian methods for analysis of biosimilar phase III trials
· SiM · 2018-05-23 · 在第 19 页
Testing hypotheses under adaptive randomization with continuous covariates in clinical trials
· SMMR · 2018-05-17 · 在第 19 页
Group sequential designs for negative binomial outcomes
· SMMR · 2018-05-17 · 在第 19 页
Causal estimands and confidence intervals associated with Wilcoxon‐Mann‐Whitney tests in randomized experiments
· SiM · 2018-05-17 · 在第 19 页
A novel cognitive disease progression model for clinical trials in autosomal‐dominant Alzheimer's disease
· SiM · 2018-05-14 · 在第 20 页
Sparse Generalized Eigenvalue Problem with Application to Canonical Correlation Analysis for Integrative Analysis of Methylation and Gene Expression Data
· Biometrics · 2018-05-11 · 在第 20 页
Bayesian sample size re-estimation using power priors
· SMMR · 2018-05-02 · 在第 21 页
Performance of intraclass correlation coefficient (ICC) as a reliability index under various distributions in scale reliability studies
· SiM · 2018-04-29 · 在第 21 页
Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis?
· SiM · 2018-04-29 · 在第 21 页
Conditional power and predictive power based on right censored data with supplementary auxiliary information
· SiM · 2018-04-22 · 在第 21 页
Comparative review of novel model‐assisted designs for phase I clinical trials
· SiM · 2018-04-22 · 在第 21 页
A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time‐to‐event data in randomized clinical trials
· SiM · 2018-04-22 · 在第 21 页
Improving testing and description of treatment effect in clinical trials with survival outcomes
· SiM · 2018-04-19 · 在第 21 页
Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes
· SiM · 2018-04-17 · 在第 22 页
Robust analysis of stepped wedge trials using cluster‐level summaries within periods
· SiM · 2018-04-10 · 在第 22 页
A predictive probability interim design for phase II clinical trials with continuous endpoints
· SiM · 2018-04-02 · 在第 22 页
Power and Sample Size Calculation Incorporating Misspecifications of the Variance Function in Comparative Clinical Trials with Over-Dispersed Count Data
· Biometrics · 2018-03-26 · 在第 23 页
Design of cancer trials based on progression‐free survival with intermittent assessment
· SiM · 2018-03-26 · 在第 23 页
Subgroup analysis with semiparametric models toward precision medicine
· SiM · 2018-03-25 · 在第 23 页
Global sensitivity analysis of clinical trials with missing patient-reported outcomes
· SMMR · 2018-03-20 · 在第 23 页
Motivating Sample Sizes in Adaptive Phase I Trials Via Bayesian Posterior Credible Intervals
· Biometrics · 2018-03-13 · 在第 24 页
Estimating Individualized Treatment Rules for Ordinal Treatments
· Biometrics · 2018-03-13 · 在第 24 页
A Group Sequential Test for Treatment Effect Based on the Fine–Gray Model
· Biometrics · 2018-03-13 · 在第 24 页
New research strategy with ambiguous implications: A comment on “Planning future studies based on the conditional power of a meta‐analysis”
· SiM · 2018-03-12 · 在第 24 页
Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials
· Biometrika · 2018-02-28 · 在第 24 页
Sample size determination for semiparametric analysis of current status data
· SMMR · 2018-02-28 · 在第 24 页
Bayesian Enhancement Two-Stage Design for Single-Arm Phase II Clinical Trials with Binary and Time-to-Event Endpoints
· Biometrics · 2018-02-21 · 在第 25 页
Controlling the type I error rate in two‐stage sequential adaptive designs when testing for average bioequivalence
· SiM · 2018-02-20 · 在第 25 页
Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials
· SiM · 2018-02-14 · 在第 25 页
Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies
· SMMR · 2018-02-13 · 在第 25 页
Sample size evaluation for a multiply matched case‐control study using the score test from a conditional logistic (discrete Cox PH) regression model
· SiM · 2018-01-31 · 在第 26 页
A recursive partitioning approach for subgroup identification in individual patient data meta‐analysis
· SiM · 2018-01-31 · 在第 26 页
Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes
· SMMR · 2018-01-22 · 在第 26 页
Modeling clustering and treatment effect heterogeneity in parallel and stepped‐wedge cluster randomized trials
· SiM · 2018-01-08 · 在第 27 页
Using Instrumental Variables for Inference About Policy Relevant Treatment Parameters
· Econometrica · 2018 · 在第 27 页